Cardlytics (NASDAQ:CDLX) Earns In-Line Rating from Analysts at Evercore ISI

Evercore ISI assumed coverage on shares of Cardlytics (NASDAQ:CDLX) in a research note published on Friday, Marketbeat.com reports. The brokerage issued an in-line rating and a $4.00 price objective on the stock.

Several other equities research analysts also recently issued reports on the stock. Northland Capmk downgraded shares of Cardlytics from a strong-buy rating to a hold rating in a research report on Friday, August 16th. Northland Securities downgraded Cardlytics from an outperform rating to a market perform rating and dropped their price target for the company from $7.00 to $5.00 in a research note on Friday, August 16th. Bank of America lowered Cardlytics from a neutral rating to an underperform rating and cut their price target for the company from $4.00 to $3.50 in a report on Thursday, August 15th. Lake Street Capital downgraded Cardlytics from a buy rating to a hold rating and decreased their price objective for the stock from $18.00 to $5.00 in a report on Thursday, August 8th. Finally, Needham & Company LLC cut Cardlytics from a buy rating to a hold rating in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating and six have given a hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Hold and a consensus price target of $6.92.

Cardlytics Stock Up 11.5 %

NASDAQ:CDLX opened at $3.59 on Friday. Cardlytics has a 1 year low of $2.89 and a 1 year high of $20.52. The stock has a 50-day moving average price of $3.77 and a two-hundred day moving average price of $7.92. The stock has a market cap of $175.13 million, a price-to-earnings ratio of -0.81 and a beta of 1.67. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 1.01.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.12. The business had revenue of $69.64 million during the quarter, compared to analyst estimates of $75.39 million. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. Cardlytics’s quarterly revenue was down 9.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.57) EPS. As a group, equities analysts expect that Cardlytics will post -1.72 earnings per share for the current year.

Insider Activity at Cardlytics

In related news, Director Scott A. Hill purchased 40,000 shares of Cardlytics stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $3.58 per share, with a total value of $143,200.00. Following the completion of the transaction, the director now owns 40,000 shares of the company’s stock, valued at approximately $143,200. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Scott A. Hill purchased 40,000 shares of the company’s stock in a transaction on Monday, August 12th. The shares were purchased at an average cost of $3.58 per share, with a total value of $143,200.00. Following the completion of the transaction, the director now owns 40,000 shares of the company’s stock, valued at $143,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Amit Gupta sold 22,699 shares of the stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $8.66, for a total transaction of $196,573.34. Following the completion of the sale, the chief operating officer now owns 150,569 shares of the company’s stock, valued at approximately $1,303,927.54. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,665 shares of company stock valued at $261,149. 4.40% of the stock is owned by insiders.

Institutional Trading of Cardlytics

Institutional investors and hedge funds have recently bought and sold shares of the business. Canton Hathaway LLC boosted its stake in shares of Cardlytics by 95.7% during the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock worth $37,000 after acquiring an additional 2,200 shares during the period. SG Americas Securities LLC acquired a new stake in Cardlytics during the 3rd quarter valued at $45,000. Creative Planning boosted its position in Cardlytics by 35.4% during the third quarter. Creative Planning now owns 29,537 shares of the company’s stock worth $95,000 after purchasing an additional 7,721 shares during the period. XTX Topco Ltd acquired a new position in shares of Cardlytics in the second quarter valued at $107,000. Finally, Quest Partners LLC raised its position in shares of Cardlytics by 160.4% in the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after purchasing an additional 11,061 shares during the period. Institutional investors own 68.10% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.